BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
580
Employees580
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
580
Employees580

BCRX Key Statistics

Market cap
2.17B
Market cap2.17B
Price-Earnings ratio
7.23
Price-Earnings ratio7.23
Dividend yield
Dividend yield
Average volume
4.91M
Average volume4.91M
High today
$8.90
High today$8.90
Low today
$7.81
Low today$7.81
Open price
$7.95
Open price$7.95
Volume
14.88M
Volume14.88M
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

The current BioCryst(BCRX) stock price is $8.74, with a market capitalization of 2.17B. The stock trades at a price-to-earnings (P/E) ratio of 7.23.

As of 2026-02-28, BioCryst(BCRX) stock has fluctuated between $7.81 and $8.90. The current price stands at $8.74, placing the stock +11.9% above today's low and -1.8% off the high.

The BioCryst(BCRX)'s current trading volume is 14.88M, compared to an average daily volume of 4.91M.

In the last year, BioCryst(BCRX) shares hit a 52-week high of $11.31 and a 52-week low of $6.00.

In the last year, BioCryst(BCRX) shares hit a 52-week high of $11.31 and a 52-week low of $6.00.

BCRX News

TipRanks 13h
BioCryst Earnings Call Highlights Profits, Pipeline Momentum

BioCryst Pharmaceuticals ((BCRX)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-l...

TipRanks 2d
BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance

An update from BioCryst ( (BCRX) ) is now available. BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and commercializing...

TipRanks 2d
BioCryst reports Q4 EPS $1.12 vs (13c) last year

Reports Q4 revenue $406.555M vs $131.534M last year. “2025 was fundamentally transformative for BioCryst (BCRX). We achieved full-year profitability for the fir...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More BCRX News

Simply Wall St 5d
Assessing BioCryst Pharmaceuticals Valuation After Recent Share Price Rebound

Advertisement What recent performance says about BioCryst Pharmaceuticals (BCRX) BioCryst Pharmaceuticals (BCRX) has been trading in a tight range, with the s...

Assessing BioCryst Pharmaceuticals Valuation After Recent Share Price Rebound

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.